中国生物医药产业加速发展，2月3日，疫苗ETF（159643）收涨1.2%，近10日净流入超1亿元。 华福证券指出，中国生物医药产业正从"快速扩张"的1.0时代，迈入以"价值与全球竞争力"为核心的2.0 时代。中国已成为全球第二大新药首发市场，在靶向蛋白质降解（TPD）等颠覆性技术领域确立全球领 导地位。产业全球竞争力最直接体现是对外许可交易的快速增长，2025年1-8月交易额已突破500亿美 元。在技术与产业层面，分化与理性回归成为主题，中国在ADC、双抗等优势领域已跻身全球第一梯 队，但内部同质化竞争加剧。资本市场回归理性，资金集中涌向中后期项目及已验证赛道的头部公司， 促使企业竞争焦点从讲故事转向拼硬实力。 疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数从沪深市场中选取涉及疫苗研发、生产 及相关生物技术等业务的上市公司证券作为指数样本，以反映疫苗与生物科技领域相关上市公司证券的 整体表现。 （文章来源：每日经济新闻） ...

（责任编辑：董萍萍 ） A股三大指数今日涨跌不一，截至收盘，沪指涨0.27%，深成指涨0.09%，创业板指跌0.57%，北证 50指数跌0.16%，沪深京三市成交额29923亿元，较上日放量708亿元，三市超3600只个股飘绿。 板块题 材上，有色金属、石油天然气、煤炭、化学化工、大豆、半导体、房地产板块涨幅居前；光伏设备、生 物疫苗、教育、军工装备、美容护理、PEEK材料概念股跌幅居前。 ETF方面，大宗商品板块掀涨停潮，金价站上5300美元，平安基金黄金股票ETF基金、国泰基金黄 金股票ETF和永赢基金黄金股ETF涨停。华泰柏瑞基金中韩半导体ETF涨7.43%。原油股走强，银华基金 油气资源ETF涨5.44%。 疫苗股领跌，疫苗ETF跌2.87%。光伏板块走低，光伏ETF易方达跌2%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数从市场中选取涉及生物制品、医疗研发 等业务的上市公司证券作为指数样本，成分股主要涵盖从事疫苗研发、生产及相关生物科技服务的企 业，以反映生物医药行业中与疫苗相关上市公司证券的整体表现。 （文章来源：每日经济新闻） 相关机构表示，商务部等九部门联合印发的《关于促进药品零售行业高质量发展的意见》，从转型、支 付、供应、整合四大维度构建行业发展框架，推动行业从"单一卖药"向"健康服务"转型。政策明确鼓励 兼并重组与横向并购，叠加医保定点待遇与基层医疗机构平权、医保个人账户家庭共济等举措，将加速 单体药店出清，行业集中度有望加速提升；优化外配处方审核，打通线下药店处方堵点，允许企业自建 药学服务平台，加速处方外流和市场扩容；鼓励零售药店扩大经营范围，开展健康咨询、中医药文化、 养老照护、便民零售等，打造综合健康服务体。 ...

Group 1 - This week, 44 new funds have started fundraising, representing a 10% increase compared to the previous week, marking the fourth consecutive week of new fund issuance remaining above 35 [1] - Public funds are showing a strong interest in new stock subscriptions, with 101 public institutions collectively acquiring 35.2871 million shares, accounting for 56.78% of the total offline allocation, with a total investment amount of 766 million yuan, also representing 56.61% of the total [2] - The Guotou Silver LOF announced the suspension of subscription services starting January 28 to protect the interests of fund shareholders [3] Group 2 - A well-known fund manager, Lan Xiaokang, has been joined by a new co-manager, Yue Xiaobo, for the China Europe Rongheng Balanced Mixed Fund, which has an asset management scale of 30.273 billion yuan and has achieved a return of 63.75% over more than two years [4] - The ETF market has seen a rebound, with all three major indices turning positive, particularly in the semiconductor and precious metals sectors, while coal and battery sectors experienced declines [4] - The semiconductor ETFs, particularly the China-Korea Semiconductor ETF, have shown significant gains, with some related ETFs rising over 4% [4][5] Group 3 - The ongoing geopolitical tensions between China and Japan have strengthened the domestic focus on the supply security and domestic substitution of key semiconductor materials, driven by the demand for AI computing power and data centers [7]

（责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com A股今日集体上涨，截至收盘，沪指涨0.18%，深成指涨0.09%，创业板指涨0.71%，北证50指数跌 0.05%，沪深京三市成交额29215亿元，较上日缩量3592亿元，三市超1900只个股飘红。 板块题材上， 贵金属、半导体、培育钻石、光伏设备、保险、军工装备、CPO、AI语料板块涨幅居前；生物疫苗、煤 炭开采加工、化学化工、电池、猪肉、白酒、旅游及酒店、电网设备板块跌幅居前。 ETF方面，半导体板块强势走高，华泰柏瑞基金中韩半导体ETF、华夏基金科创半导体ETF、华泰 柏瑞基金科创半导体设备ETF分别涨4.51%、3.59%、3.52%。科创100指数午后拉升，国泰基金科创板 100ETF涨3.41%。CPO板块久违反弹，创业板人工智能ETF华宝涨2.76%。 国证2000ETF工银跌4.93%。疫苗板块走低，疫苗ETF、疫苗ET ...

Market Overview - The three major A-share indices showed mixed performance in the morning session, with the Shanghai Composite Index up by 0.03%, the Shenzhen Component down by 0.37%, and the ChiNext Index up by 0.44% [1] - The North China 50 Index fell by 1.26%, and the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1.89 trillion yuan, a decrease of 372.6 billion yuan compared to the previous day [1] - Over 4,400 stocks in the market experienced declines [1] Sector Performance - The computing power hardware industry chain strengthened, with CPO and memory sectors leading the gains [1] - Gold and semiconductor concept stocks also showed strength, while sectors such as consumer goods, lithium batteries, rare earth permanent magnets, innovative pharmaceuticals, and AI applications weakened [1] ETF Performance - In the ETF market, the semiconductor equipment sector saw significant gains, with the Huaxia Fund's Sci-Tech Semiconductor ETF, the Huatai-PB Fund's Sci-Tech Semiconductor Equipment ETF, and the Penghua Sci-Tech Semiconductor Equipment ETF all rising over 3% [1] - The CPO sector remained resilient, with the Guotai Fund's Communication ETF and the Fuguo Fund's Communication Equipment ETF increasing by 2.31% and 2.27%, respectively [1] - Conversely, the Guotai 2000 ETF from ICBC fell by 7%, and the vaccine sector declined, with the Vaccine ETF and the Fuguo Vaccine ETF both dropping by 5% [1] - The lithium battery sector faced a broad decline, with the Lithium Battery ETF and the Southern Battery ETF both down by 3% [1]

Core Insights - The Chinese pharmaceutical industry has successfully transitioned from old to new growth drivers between 2015 and 2025, with innovation replacing generics and an enhanced ability to expand internationally [1] Group 1: Industry Transformation - The Chinese innovation sector has reached a significant scale, with traditional pharmaceutical companies successfully transforming into innovative entities, leading to the rapid rise of innovative drug companies [1] - The ability of Chinese pharmaceutical companies to expand internationally has accelerated, making them a key source of innovation for multinational corporations (MNCs), with medical devices and supply chains gaining a strong global presence [1] Group 2: Demand and Payment Dynamics - The aging population is accelerating, leading to an increased demand for chronic disease management [1] - Healthcare insurance revenue continues to grow steadily, while the National Healthcare Security Administration is actively promoting the development of commercial insurance to build a multi-tiered payment system [1] Group 3: Technological Advancements - New technologies are driving industry transformation, with the AI technology wave expected to unlock new growth logic in the pharmaceutical sector, including advancements in brain-computer interfaces, early cancer screening, and AI in healthcare [1] Group 4: Investment Opportunities - Looking ahead to 2026, there is continued optimism for the pharmaceutical technology sector, particularly those focused on innovation [1] Group 5: ETF Overview - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which selects listed companies involved in vaccine research, production, and related services from the Shanghai and Shenzhen markets to reflect the overall performance of the vaccine industry chain [1]

Core Insights - The Nipah virus has resurfaced in India, particularly in West Bengal, with 5 confirmed cases and around 100 individuals under home quarantine. This news has led to a rapid increase in the A-share market for flu and virus prevention sectors [1] - The vaccine ETF (159643) saw a net inflow of over 50 million yuan yesterday, indicating strong investor interest in vaccine-related investments [1] Industry Analysis - East Wu Securities highlights that the therapeutic cancer vaccine sector is entering a breakthrough development window, shifting the industry towards efficient and personalized immunotherapy [1] - mRNA vaccines possess three core competitive advantages over traditional technologies: rapid production capabilities and low costs, enhanced safety through non-integration with host genomes, and high flexibility in antigen design for personalized treatment [1] Investment Vehicle - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, and related services from the Shanghai and Shenzhen markets, reflecting the overall performance of the vaccine industry chain [1]

1月26日，疫苗ETF（159643）收涨近6%，中国创新药产业已具规模 华源证券指出，经过2015-2025年的十年创新转型，中国医药产业基本完成了新旧增长动能转换， 创新替代仿制，出海能力提升。中国创新产业已具规模，传统Pharma已完成创新的华丽转身；出海能 力加速提升，中国药企已成为MNC非常重视的创新转换来源，医疗设备、供应链等已在全球范围内占 据较高地位。需求端和支付端持续推动新增量：老龄化持续加速，心脑血管、内分泌、骨科等慢性疾病 需求持续提升；医保收支仍在稳健增长，同时医保局积极推动商业保险的发展，构建多层次支付体系。 新技术也在加速行业变革，AI大科技浪潮下，医药有望释放新的成长逻辑，脑机接口、肿瘤早筛、AI 医疗等快速发展。 疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数从沪深市场中选取涉及疫苗研发、 生产及相关服务等业务的上市公司证券作为指数样本，以反映生物科学领域内专注于疫苗产业链的上市 公司证券的整体表现。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随 ...

Group 1 - The core viewpoint of the article highlights that the Chinese pharmaceutical industry is at the starting point of a global value reassessment, as emphasized during the JPM conference [1] - The domestic CXO industry is transitioning from a "cost advantage" model to a dual-driven approach of "technology + scale," leveraging capabilities in areas such as ADC, dual antibodies, and GLP-1 to evolve from "intermediate suppliers" to "global innovation enablers" [1] - There is a noticeable acceleration in the globalization of domestic pharmaceutical companies, with key trends including the iteration of technology platforms like ADC, multi-antibodies, and small nucleic acids, as well as significant transactions exceeding $10 billion with multinational corporations (MNCs) [1] Group 2 - The year 2026 is identified as a critical milestone for domestic pharmaceutical companies, marking a period of intensive verification of transformation effectiveness, with many companies initiating global registration studies, key data readouts, and new product applications [1] - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which focuses on bioproducts, vaccine research and development, and related services, reflecting the overall performance of listed companies engaged in vaccine production, research, and sales [1]